Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus in Refractory Rheumatoid Arthritis
NCT02837978Phase 4Completed
- Start
- Jan 2015
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus + Wuzhi capsule in rheumatoid arthritis (RA) (2 arms). Primary endpoint: Disease Activity Score 28-ESR at 144 weeks. Started Jan 2015; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02837978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837978.